Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8697636rdf:typepubmed:Citationlld:pubmed
pubmed-article:8697636lifeskim:mentionsumls-concept:C0220847lld:lifeskim
pubmed-article:8697636lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8697636lifeskim:mentionsumls-concept:C0010403lld:lifeskim
pubmed-article:8697636lifeskim:mentionsumls-concept:C1155229lld:lifeskim
pubmed-article:8697636lifeskim:mentionsumls-concept:C0443199lld:lifeskim
pubmed-article:8697636lifeskim:mentionsumls-concept:C0205430lld:lifeskim
pubmed-article:8697636lifeskim:mentionsumls-concept:C0597551lld:lifeskim
pubmed-article:8697636pubmed:issue1lld:pubmed
pubmed-article:8697636pubmed:dateCreated1996-9-3lld:pubmed
pubmed-article:8697636pubmed:abstractTextIn this study we have evaluated the prevalence of antibodies against core region peptides (residues 1-28, 21-38 and 51-68), the envelope 1, the non-structural (NS) 4 and 5 proteins of hepatitis C virus (HCV) in sera from 65 chronically HCV-infected patients, 47 with mixed cryoglobulinaemia (MC+) and 18 without (MC-). The major binding sites were located within the core region. Regions 1-28 and 51-68 were recognized by a similar proportion of MC+ and MC- patients, while peptide 21-38 was less frequently detected by samples from MC+ patients (65.5% versus 100%, P = 0.011). The patterns of the reactions showed a minimum of three binding sites: one, located within region 51-68, was shared by both groups; a second determinant was identified at residues 1-21 for MC+ patients and at residues 28-38 for MC- patients; a third, not exactly localized, lay between residues 1 and 38. Recognition of NS5 peptides was not significantly different between MC+ and MC- patients, but while the former mostly reacted either with peptide 1 (residues 2294-2309) (five of 15 sera) or with peptide 2 (residues 2304-2319) (nine of 15 sera), the latter group showed a more scattered reaction. Antibodies to HCV peptides prevalently belonged to IgGl subclass. However, whereas IgGl antibodies against peptide 21-38 and peptide 1 of NS5 were more frequently found in MC- rather than in MC+ patients (100% versus 63.8%, P = 0.003, and 22.2% versus 4.2%, P = 0.025, respectively), IgG3 antibodies against region 1-28 were more frequent in MC+ patients (53.19% versus 16.6%, P = 0.0078). Overall, the data suggest that a differential humoral immune response to HCV antigens occurs in patients with and without cryoglobulinaemia.lld:pubmed
pubmed-article:8697636pubmed:languageenglld:pubmed
pubmed-article:8697636pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8697636pubmed:citationSubsetIMlld:pubmed
pubmed-article:8697636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8697636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8697636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8697636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8697636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8697636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8697636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8697636pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8697636pubmed:statusMEDLINElld:pubmed
pubmed-article:8697636pubmed:monthJullld:pubmed
pubmed-article:8697636pubmed:issn0009-9104lld:pubmed
pubmed-article:8697636pubmed:authorpubmed-author:GabrielliAAlld:pubmed
pubmed-article:8697636pubmed:authorpubmed-author:ZhangZ XZXlld:pubmed
pubmed-article:8697636pubmed:authorpubmed-author:AmorosoAAlld:pubmed
pubmed-article:8697636pubmed:authorpubmed-author:ClementiMMlld:pubmed
pubmed-article:8697636pubmed:authorpubmed-author:ManzinAAlld:pubmed
pubmed-article:8697636pubmed:authorpubmed-author:SavoldiSSlld:pubmed
pubmed-article:8697636pubmed:authorpubmed-author:CandelaMMlld:pubmed
pubmed-article:8697636pubmed:authorpubmed-author:CherubiniGGlld:pubmed
pubmed-article:8697636pubmed:authorpubmed-author:SallbergMMlld:pubmed
pubmed-article:8697636pubmed:issnTypePrintlld:pubmed
pubmed-article:8697636pubmed:volume105lld:pubmed
pubmed-article:8697636pubmed:ownerNLMlld:pubmed
pubmed-article:8697636pubmed:authorsCompleteYlld:pubmed
pubmed-article:8697636pubmed:pagination59-64lld:pubmed
pubmed-article:8697636pubmed:dateRevised2008-11-20lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:meshHeadingpubmed-meshheading:8697636-...lld:pubmed
pubmed-article:8697636pubmed:year1996lld:pubmed
pubmed-article:8697636pubmed:articleTitleDifferential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia.lld:pubmed
pubmed-article:8697636pubmed:affiliationIstituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica, Università di Ancona, Italy.lld:pubmed
pubmed-article:8697636pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8697636pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:8697636pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8697636lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8697636lld:pubmed